Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Senti Biosciences Holdings, Inc.
A biotech company that builds cells engineered with "gene circuits" — biological software programmed in so the cells can sense, compute, and respond much like a computer. Its therapies target hard-to-treat cancers, and the engineered cells are designed to attack tumors while sparing healthy tissue. Founded in 2016 by synthetic-biology pioneers, the name "Senti" comes from the cells' ability to "sense" their environment.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 5.01 Changes in Control of Registrant · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 8.01 Other Events · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 3.02 Unregistered Sales of Equity Securities · 5.01 Changes in Control of Registrant · 9.01 Financial Statements and Exhibits
8.01 Other Events
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement